Key Points {#FPar1}
==========

In aspirin-intolerant patients with previous stroke after acute myocardial infarction (AMI), combination therapy with clopidogrel and dipyridamole had no additional survival benefit compared with clopidogrel alone.Combination clopidogrel--dipyridamole therapy in patients with previous stroke after AMI had no benefit on event-free survival in recurrent stroke, intracerebral hemorrhage, gastrointestinal bleeding, or myocardial infarction.Adding dipyridamole to clopidogrel for secondary stroke prevention after AMI is not recommended, according to this study.

Introduction {#Sec1}
============

Both stroke and acute coronary syndrome can lead to disability and death worldwide \[[@CR1], [@CR2]\]. Antiplatelet therapy reduces the risk of recurrent non-cardioembolic stroke and other thromboembolic events \[[@CR1], [@CR3], [@CR4]\]. Clopidogrel is an alternative monotherapy if patients are allergic or intolerant to aspirin \[[@CR5]--[@CR7]\]. The Clopidogrel Versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE) trial reported an additional effect of clopidogrel versus aspirin alone in patients with symptomatic atherosclerosis, with clopidogrel showing remarkable benefit in reducing myocardial infarction (MI) in the most severe groups of patients, providing a 19% relative risk reduction \[[@CR2], [@CR8]\].

For secondary ischemic stroke prevention, synergistic effect between aspirin and dipyridamole for secondary prevention was shown in the second European Stroke Prevention Study (ESPS2) \[[@CR9]\]. Combination therapy with aspirin and dipyridamole is a first-line treatment compared with aspirin or clopidogrel alone \[[@CR10], [@CR11]\]. Non-inferiority of clopidogrel in secondary stroke prevention when compared with extended-release dipyridamole plus aspirin was also shown in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial \[[@CR12]\].

No studies have investigated the combination therapy of dipyridamole and clopidogrel in stroke prevention and the long-term outcomes in aspirin-intolerant patients with acute myocardial infarction (AMI) and previous stroke. The aim of our study was to analyze the efficacy and safety of dipyridamole and clopidogrel in secondary prevention of stroke, and to evaluate the long-term outcomes in patients with previous ischemic stroke after AMI.

Methods {#Sec2}
=======

Data Source {#Sec3}
-----------

The National Health Insurance (NHI) program, established by the Taiwanese government, has provided universal health coverage to approximately 99% of residents in Taiwan since 1995. A computerized database \[Taiwan's National Health Insurance Research Database (NHIRD)\], consisting of data collected from more than 23 million patients, includes inpatient medical records on demographic information and International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnostic codes, and drug codes.

Data for this study, which was approved by the Human Research Committee of Kaohsiung Veterans General Hospital, were collected from the NHIRD from January 2000 to December 2012.

Definition of the Acute Myocardial Infarction (AMI) Population {#Sec4}
--------------------------------------------------------------

The AMI cohort, constituting 186,326 cases, was retrieved from the NHIRD in Taiwan between January 2000 and December 2012, with a primary diagnosis of AMI (ICD-9-CM code 410-410.92). We excluded patients who were under 18 years or over 120 years of age, who had previous admissions for AMI, and whose sex was undetermined, resulting in a total of 186,112 patients being included in the analysis (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Identification process of the study cohort. *AMI* acute myocardial infarction, *ICD* International Classification of Diseases, *MI* myocardial infarction, *CVA* cerebrovascular accident

Study Population {#Sec5}
----------------

Among the AMI cohort of 186,112 cases, 78,607 patients who were previously diagnosed with stroke (ICD-9-CM codes 430-438, A290-294) were analyzed. In our final analysis, we studied 4637 patients in the clopidogrel group and 208 patients in the clopidogrel--dipyridamole group (Fig. [1](#Fig1){ref-type="fig"}). Other comorbidities were also defined according to ICD-9-CM diagnostic codes, e.g. hypertension (ICD-9-CM codes 401-405), dyslipidemia (ICD-9-CM code 272), peripheral vascular disease (PVD; ICD-9-CM codes 443.9, 441, 441.9, 785.4 and V43.4, or procedure code 38.48), diabetes mellitus (DM; ICD-9-CM code 250), end-stage renal disease (ESRD; ICD-9-CM code 585), and chronic obstructive pulmonary disease (COPD; ICD-9-CM codes 491, 492 and 496). Indications of percutaneous coronary intervention (PCI) followed current guidelines \[[@CR13]--[@CR16]\].

We standardized medication status by using 'index' in-hospital and discharge medications. All patients were prescribed single antiplatelet therapy with clopidogrel, or dual antiplatelet therapy with clopidogrel--dipyridamole, after index discharge.

Outcome Analysis {#Sec6}
----------------

The NHI premium is paid monthly and coverage can easily be canceled at the time of death. We defined survival based on the difference between the date of hospitalization and the end date of NHI coverage. Previous studies determined the validity of in-hospital mortality records in the NHIRD by cross-comparing them with death records from medical center electronic medical records, thus proving that the accuracy of death records in the NHIRD was high, within a maximum error of 1 month. Therefore, this database is a valid resource for population research in cardiovascular diseases \[[@CR17]--[@CR20]\].

Statistical Analysis {#Sec7}
--------------------

For data analysis, SAS software version 9.4 (SAS Institute, Inc., Cary, NC, USA) was used. All variables were calculated using descriptive statistics. Percentile values were used to express categorical data, which were analyzed using the Chi-square test, and mean and standard deviation (SD) were applied to express continuous variables, which were analyzed using a paired *t* test. A *p* value \< 0.05 was considered statistically significant.

Cox proportional hazard regression analysis was used to calculate the hazard ratio (HR) and associated 95% confidence intervals (CIs) for significant variables, including PVD, ESRD, COPD, etc., while Kaplan--Meier cumulative survival curves were used to analyze outcomes between the clopidogrel and clopidogrel--dipyridamole groups based on sex, age, ST elevation myocardial infarction (STEMI), non-STEMI (NSTEMI), DM, and PCI. Log-rank tests with a *p* value \< 0.05 were used to determine statistical significance.

Results {#Sec8}
=======

The descriptive characteristics of 4637 patients in the clopidogrel group and 208 patients in the clopidogrel--dipyridamole group are listed in Table [1](#Tab1){ref-type="table"}. The two groups were comparable with regard to age, sex, atrial fibrillation, comorbidities, PCI, and thrombolytic therapy (Table [1](#Tab1){ref-type="table"}). For in-hospital and discharge medications, there was no difference between the two groups in the use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), statins, β-blockers, nicorandil, atropine and dopamine. No patients in this study took warfarin or non-vitamin K antagonist oral anticoagulants. However, patients in the clopidogrel--dipyridamole group were more frequently prescribed nitrate (*p* = 0.0001).Table 1Characteristics of patients with a previous history of stroke after first hospitalization for AMI in the subgroups of the clopidogrel and clopidogrel--dipyridamole groupsCharacteristicsClopidogrel (*N* = 4637) (%)Clopidogrel--dipyridamole (*N* = 208) (%)*p* valueMale2661 (57.4)125 (60.10)0.4393Age ≥75 years2686 (57.9)132 (63.5)0.1133AMI type STEMI1050 (22.6)43 (20.7)0.5059 NSTEMI3587 (77.4)165 (79.3)Comorbidities Hypertension3649 (78.7)163 (78.4)0.9101 Dyslipidemia1806 (39.0)82 (39.4)0.8906 Diabetes mellitus2526 (54.5)117 (53.3)0.6150 Peripheral vascular disease297 (6.4)13 (6.3)0.9288 End-stage renal disease411 (8.9)18 (8.7)0.9171 Chronic obstructive pulmonary disease853 (18.4)45 (21.6)0.2395 Atrial fibrillation986 (21.3)55 (26.4)0.0753Treatment Percutaneous coronary intervention1525 (32.9)60 (28.9)0.2242 Thrombolytic therapy20 (0.43)2 (0.96)0.2658In-hospital medications Heparin or LMWH2745 (59.2)123 (59.1)0.9855 Dopamine1120 (24.2)54 (26.0)0.5516 Atropine111 (2.4)5 (2.4)1.0000Discharge medications ACEIs or ARBs2327 (50.2)116 (55.8)0.1150 Statins1018 (22.0)45 (21.6)0.9133 β-blockers2046 (44.1)93 (44.7)0.8673 Aldosterone antagonists678 (14.6)26 (12.5)0.3957 Nitrates3551 (76.6)183 (88.0)0.0001 Nicorandil481 (10.4)27 (13.0)0.2298 Warfarin0 (0.0)0 (0.0) NOACs0 (0.0)0 (0.0)*AMI* acute myocardial infarction, *ACEIs* angiotensin-converting enzyme inhibitors, *ARBs* angiotensin receptor blockers, *LMWH* low-molecular-weight heparin, *NOACs* non-vitamin K antagonist oral anticoagulants, *STEMI* ST elevation myocardial infarction, *NSTEMI* non-ST elevation myocardial infarction

Overall, the 12-year survival rate was not different between the two groups of patients after first AMI (log-rank *p* = 0.6247) (Fig. [2](#Fig2){ref-type="fig"}a). In the sex subgroup analysis, long-term outcomes of the clopidogrel group did not differ from the clopidogrel--dipyridamole group for both males (log-rank *p* = 0.7431) (Fig. [2](#Fig2){ref-type="fig"}b) and females (log-rank *p* = 0.6788) (Fig. [2](#Fig2){ref-type="fig"}c). In the age subgroup analysis, there was no survival difference between the two groups regardless of whether patients were older (log-rank *p* = 0.6833) (Fig. [2](#Fig2){ref-type="fig"}d) or younger (log-rank *p* = 0.5630) (Fig. [2](#Fig2){ref-type="fig"}e).Fig. 2Kaplan--Meier survival curves with first AMI and previous stroke in overall, sex-specific, and age-specific subanalyses (**a--e**). Overall, the 12-year survival rate was not different between patients in the two groups after first AMI \[log-rank *p* = 0.6247\] (**a**). In the sex subgroup analysis, the long-term outcomes of the clopidogrel group did not differ from those of the clopidogrel--dipyridamole group among the male \[log-rank *p* = 0.7431\] (**b**) or female subgroups \[log-rank *p* = 0.6788\] (**c**). In the age subgroup analysis, there was no survival difference between the two groups, regardless of whether patients were older \[log-rank *p* = 0.6833\] (**d**) or younger \[log-rank *p* = 0.5630\] (**e**). *AMI* acute myocardial infarction

There were no statistical differences between the two therapeutic strategies in patients with (log-rank *p* = 0.3436) (Fig. [3](#Fig3){ref-type="fig"}a) or without diabetes (log-rank *p* = 0.7833) (Fig. [3](#Fig3){ref-type="fig"}b), and no superiority of either therapy was observed in subgroups of different types of MI, regardless of STEMI (log-rank *p* = 0.4066) (Fig. [3](#Fig3){ref-type="fig"}c) or NSTEMI (log-rank *p* = 0.9812) status (Fig. [3](#Fig3){ref-type="fig"}d). Similar effects between the two strategies were observed in patients who did (log-rank *p* = 0.8185) (Fig. [3](#Fig3){ref-type="fig"}e) or did not undergo PCI therapy (log-rank *p* = 0.8838) (Fig. [3](#Fig3){ref-type="fig"}f).Fig. 3Kaplan--Meier survival curves after first AMI in the DM, AMI type, and PCI subgroups of patients (**a--f**). There were no statistical differences between the two therapeutic strategies in patients with \[log-rank *p* = 0.3436\] (**a**) or without \[log-rank *p* = 0.7833\] DM (**b**). No superiority of any therapy in subgroups of different types of myocardial infarction was observed, regardless of AMI type \[log-rank *p* = 0.4066\] (**c**), and log-rank *p* = 0.9812 (**d**). There were similar effects of the two strategies in patients who did \[log-rank *p* = 0.8185\] (**e**) or did not \[log-rank *p* = 0.8838\] undergo PCI therapy (**f**). *AMI* acute myocardial infarction, *DM* diabetes mellitus, *PCI* percutaneous coronary intervention, *STEMI* ST elevation myocardial infarction, *NSTEMI* non-ST elevation myocardial infarction

No difference in stroke-free survival (log-rank *p* = 0.6842) (Fig. [4](#Fig4){ref-type="fig"}b) was observed between the two groups of patients after AMI. Clopidogrel plus dipyridamole did not lead to worse intracerebral hemorrhage (ICH; log-rank *p* = 0.6191) (Fig. [4](#Fig4){ref-type="fig"}c) or gastrointestinal (GI) bleeding-free survival (log-rank *p* = 0.9539) (Fig. [4](#Fig4){ref-type="fig"}d). Moreover, the clopidogrel--dipyridamole combination did not further improve the recurrent MI-free survival rate (log-rank *p* = 0.8344) (Fig. [4](#Fig4){ref-type="fig"}a).Fig. 4Event-free survival curves of patients with first AMI and previous stroke (**a--d**). There was no difference in stroke-free survival \[log-rank *p* = 0.6842\] (**b**) between the two groups of patients after AMI. Clopidogrel plus dipyridamole did not lead to worse intracerebral hemorrhage-free survival \[log-rank *p* = 0.6191\] (**c**) or gastrointestinal bleeding-free survival \[log-rank *p* = 0.9539\] (**d**). Furthermore, the combination with dipyridamole did not improve recurrent myocardial infarction-free survival \[log-rank *p* = 0.8344\] (**a**). *AMI* acute myocardial infarction

Cox proportional hazard regression analysis indicated HRs for mortality across different variables (Table [2](#Tab2){ref-type="table"}). The HR for mortality was higher in older patients (HR 1.67), and in patients with DM (HR 1.20), PVD (HR 1.50), ESRD (HR 1.28), and COPD (HR 1.11). In contrast, PCI was shown to reduce the risk of mortality in patients after AMI (HR 0.57). Furthermore, the use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) (HR 0.70), statins (HR 0.83), and β-blockers (HR 0.86) showed a significant survival benefit. Dipyridamole did not contribute to AMI-free survival (HR 0.98).Table 2Cox proportional hazard regression on survival of patients with a previous history of stroke after first acute myocardial infarction (*N* = 4845)VariablesHR (95% CI)*p*-valueSex (male vs. female)1.00 (0.94--1.07)0.9861Age (≥ 75 vs. \< 75 years)1.67 (1.55--1.79)\<0.0001Hypertension (yes vs. no)1.00 (0.92--1.08)0.8953Dyslipidemia (yes vs. no)0.95 (0.87--1.04)0.2594Diabetes mellitus (yes vs. no)1.20 (1.12--1.28)\<0.0001Peripheral vascular disease (yes vs. no)1.50 (1.32--1.70)\<0.0001End-stage renal disease (yes vs. no)1.28 (1.14--1.44)\<0.0001Chronic obstructive pulmonary disease (yes vs. no)1.11 (1.02--1.21)0.0135Percutaneous coronary intervention (yes vs. no)0.57 (0.53--0.61)\<0.0001ACEIs or ARBs (yes vs. no)0.70 (0.65--0.75)\<0.0001Statins (yes vs. no)0.83 (0.74--0.92)0.0007β-blockers (yes vs. no)0.86 (0.80--0.92)\<0.0001Heparin or low-molecular-weight heparin (yes vs. no)1.03 (0.96--1.10)0.4107Dipyridamole (yes vs. no)0.98 (0.84--1.15)0.82*ACEIs* angiotensin-converting enzyme inhibitors, *ARBs* angiotensin receptor blockers, *CI* confidence interval, *HR* hazard ratio

A forest plot of HRs (Fig. [5](#Fig5){ref-type="fig"}) indicated that dipyridamole had no benefit in any subgroup regardless of sex, age (younger or older than 75 years), comorbidities (hypertension, dyslipidemia, DM, PVD, ESRD, COPD), PCI, or medications (ACEIs or ARBs, statins, β-blockers, heparin or low-molecular-weight heparin).Fig. 5Forest plot of hazard ratios in patients with first AMI and previous stroke. Dipyridamole showed no benefit in any subgroup analysis regardless of sex, age (younger or older than 75 years), comorbidities (HTN, dyslipidemia, DM, PVD, ESRD, COPD), PCI, or medications (ACEIs or ARBs, statins, β-blockers, heparin, or LMWH). *ACEI* angiotensin-converting enzyme inhibitor, *ARB* angiotensin receptor blocker, *COPD* chronic obstructive pulmonary disease, *DM* diabetes mellitus, *ESRD* end-stage renal disease, *LMWH* low-molecular-weight heparin, *PVD* peripheral vascular disease, *HTN* hypertension, *PCI* percutaneous coronary intervention, *HR* hazard ratio, *CI* confidence interval, *AMI* acute myocardial infarction

Discussion {#Sec9}
==========

There was no previous study to investigate clopidogrel-dipyridamole combination therapy for secondary stroke prevention and long-term outcome in aspirin-intolerant patients with AMI and old stroke.There was no difference in long-term outcome between the clopidogrel and clopidogrel--dipyridamole groups. In addition, the two groups had comparable event-free survival in recurrent stroke, ICH, GI bleeding, and MI.

Putative Mechanism of the Combination Therapy Between Dipyridamole and Aspirin {#Sec10}
------------------------------------------------------------------------------

Adenosine diphosphate (ADP) suppresses thromboxane A2 and blocks the effect of aspirin \[[@CR21]\], while dipyridamole eliminates the above-mentioned suppression via the inhibition of ADP uptake by platelets \[[@CR22]\]. The benefit of dipyridamole comes from its effect on the vascular wall beyond platelet inhibition \[[@CR23], [@CR24]\]. Previous animal studies demonstrated the synergistic antithrombotic effects of dipyridamole and aspirin in rabbits, which were also demonstrated in human trials \[[@CR9], [@CR25]--[@CR29]\]. Multiple pharmacologic mechanisms and the vasodilation effect of dipyridamole contribute to the synergic effect of aspirin and dipyridamole in stroke prevention.

Clopidogrel--Dipyridamole Combination did not Improve Overall Outcomes or Prevent Secondary Stroke Recurrence After AMI {#Sec11}
-----------------------------------------------------------------------------------------------------------------------

Clopidogrel is a type of ADP receptor (P2Y12) inhibitor that differs from the phosphodiesterase (PDE) inhibitor dipyridamole. Although more than 50% of Chinese people have a loss-of-function mutation of cytochrome P450 (CYP) 2C19 that renders clopidogrel less effective \[[@CR30]\], dipyridamole did not seem to have additive effect with clopidogrel (log-rank *p* = 0.6247) (Fig. [2](#Fig2){ref-type="fig"}a). No synergic effect between clopidogrel and dipyridamole was noted, which could be attributed to the fact that both antiplatelet agents shared a common function of the inhibition of platelet aggregation \[[@CR29]\].

In our national database, a higher percentage of AMI patients had previous stroke event. Previous studies validated the diagnostic accuracy of ICD codes to identify patients with stroke. Furthermore, 60% of stroke patients were found to have AMI \[[@CR31]\], and another AMI registry with a mean age of 65 years revealed that 20% of AMI patients had previous stroke \[[@CR32]\]. The relative incidence of stroke compared with AMI was remarkably higher and had linear growth in those older than 65 years of age \[[@CR33]\]. In our study, 57.9% of patients in the clopidogrel group and 63.5% of patients in the clopidogrel--dipyridamole group were aged older than 75 years. The relatively older patients in our nationwide study might partly explain the higher proportion of patients with previous stroke.

Patients in the clopidogrel--dipyridamole group were prescribed with nitrate more frequently (*p* = 0.0001); however, there were comparable comorbidities, PCI, or other medications between the two groups. The frequent prescription of nitrate might be more symptomatic, but there was insufficient evidence to ascribe the frequency of nitrate prescription to the severity of disease. A previous study also reported that nitrate therapy after AMI does not affect prognosis \[[@CR34]\].

Clopidogrel--Dipyridamole had No Benefit in Diabetes Mellitus and Peripheral Vascular Disease Patients {#Sec12}
------------------------------------------------------------------------------------------------------

Diabetes increases the burden of stroke and PVD, and PVD is complicated by high rates of MI and stroke \[[@CR35], [@CR36]\]. Non-aspirin antiplatelet drugs (clopidogrel and dipyridamole) largely drive the benefits in PVD patients \[[@CR36]\]. In patients with MI and PVD, as well as patients with concomitant DM and atherosclerotic vascular disease, clopidogrel is superior to aspirin as monotherapy \[[@CR4], [@CR8], [@CR37]--[@CR39]\].

In DM and PVD patients with a previous history of stroke after AMI, the efficacy and safety of clopidogrel--dipyridamole combination therapy are unknown, and our study revealed no additional benefits of this combination therapy.

Clopidogrel--Dipyridamole did not Increase Hemorrhage-Related Mortality {#Sec13}
-----------------------------------------------------------------------

Patients who experience stroke are at high risk for recurrent stroke, MI, and vascular death \[[@CR40]\]. The aspirin--dipyridamole combination did not increase the frequency of bleeding events \[[@CR23]\]. Clopidogrel monotherapy is an alternate to aspirin plus dipyridamole, with a similar risk of bleeding \[[@CR8], [@CR41]--[@CR44]\], while dipyridamole reduces the risk of recurrent stroke without excess bleeding \[[@CR23]\].

No previous studies have evaluated the hemorrhagic complications of the clopidogrel--dipyridamole combination. Our study did not observe an increase in ICH or GI bleeding-related mortality in the combination group.

Study Limitations {#Sec14}
-----------------

There were several limitations in the present study. First, this was a non-randomized, retrospective cohort study, and the small sample size in the clopidogrel--dipyridamole group was notable, although it was acquired from a large national database. Clinical prescription and long-term follow-up of the clopidogrel--dipyridamole combination was not routine practice. This study provided important information of antiplatelet strategies for clinical practitioners. Second, the healthcare claims data did not contain objective assessments for evaluating the severity of stroke patients, such as the modified Rankin Scale, the National Institutes of Health Stroke Scale, etc. Moreover, cardiac enzyme and systolic function for evaluating severity and impact after AMI were not available. Third, indices of the risk factors were nonexistent, including body mass index, glycated hemoglobin, blood pressure, smoking history, and ankle--brachial index. However, a previous study reported that smoking duration had a linear relationship with COPD \[[@CR45]\], thus the morbidity rate of COPD might be correlated with smoking history. In this study, there was no difference in COPD percentage between the two groups (*p* = 0.2395), which showed comparable proportion of patients with smoking history. Fourth, standard laboratory tests, including the assessment of renal function, liver function, and coagulation function, were not available and these factors may interfere with drug--drug interactions, bleeding risk, and medication administration. Fifth, a meta-analysis indicated that extended-release and high-dose dipyridamole are more effective than immediate-release and low-dose dipyridamole \[[@CR9], [@CR23], [@CR26], [@CR29]\]. The number of patients in the clopidogrel--dipyridamole combination group was relatively small, which limited advanced subgroup analysis. Further prospective, randomized studies are required to confirm our findings.

Strengths of this Study {#Sec15}
-----------------------

This is the first study to investigate the combination therapy of dipyridamole and clopidogrel in stroke prevention and to evaluate the long-term outcomes in aspirin-intolerant patients with AMI and previous stroke. This nationwide study has a large sample size and a long-term follow-up of 12 years to analyze the outcomes of the two therapeutic strategies. The large sample size reduces the variability in sampling statistics. Our study offers information on antiplatelet strategies for physicians in clinical practice.

Conclusions {#Sec16}
===========

This nationwide study indicated that there were no differences in 12-year survival rates between clopidogrel and clopidogrel--dipyridamole groups, regardless of age, sex, type of MI, intervention or medical therapy. Event-free survival in recurrent stroke, ICH, GI bleeding, and myocardial infarction were not different between the clopidogrel and clopidogrel--dipyridamole groups.
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